OPKO and Bristol-Myers Squibb will examine the utility of OPKO’s proprietary platform technology for diagnosis of Alzheimer’s disease.
The companies will also investigate the use of novel technology for identifying individuals with early stage cognitive impairment that are at risk of developing Alzheimer’s disease.
OPKO chairman and CEO Phillip Frost said the company pleased to work with Bristol-Myers to generate additional validation data that may expedite the approval and marketing of the simple blood test for Alzheimer’s disease and cognitive disorders that may precede it.
OPKO’s simple blood tests, which are based on its proprietary platform, are being developed to identify biomarkers for a wide variety of diseases such as neurodegenerative disorders and various malignancies.
